Clinical Study on the Diagnostic and Predictive Value of MRI Multiparameter Functional Sequences in Renal Tumors

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074716

Enrollment

Unknown

Registered

2023-08-14

Start date

2023-09-01

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal tumor

Interventions

Gold Standard: Pathologically confirmed renal malignancy

Index test:T2 weighted imaging (T2WI), T1 weighted imaging (T1WI), diffusion weighted imaging (DWI), multi-parameter functional MR

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Pathologically confirmed renal malignancy; (2) Routine MRI, MRI new advanced diffusion, DCE, ASL, QSM and fat quantification were performed within 2 weeks before pathological examination.

Exclusion criteria

Exclusion criteria: (1) Renal tumors that have undergone treatment prior to MRI advanced diffusion, DCE, ASL, QSM, and fat quantification sequence scans; (2) Patients who have undergone renal puncture within 2 weeks prior to MRI advanced diffusion, DCE, ASL, QSM, and fat quantification sequence scanning; (3) Due to motion artifacts or other reasons leading to poor image quality, it is not possible to perform post-processing of MRI advanced diffusion, DCE, ASL, QSM, and fat quantification sequences.

Design outcomes

Primary

Measure	Time frame
ROC Curve;Area Under Curve (AUC);	—

Secondary

Measure	Time frame
specificity;sensitivity;accuracy;	—

Countries

China

Contacts

Public ContactDuan Xiaohui

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

duanxh5@mail.sysu.edu.cn+86 135 1276 2365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026